Session VI: Presentation of Selected Non-Colorectal Cancer Abstracts - Esophageal and Stomach Cancers

Chair(s)

• 

  Florian Lordick, MD, PhD

  Leipzig University Medical Center
  Leipzig, Germany
• 

  Anna Wagner, MD

  Lausanne University Hospital, University of Lausanne
  Lausanne, Switzerland

Presentations:

• 08:00 – 08:10 CEST

  O-3: Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
  

  Abstract Presenter: Lucjan Wyrwicz, MD PhD – Maria Sklodowska-Curie National Cancer Research Institute
• 08:10 – 08:20 CEST

  O-4: GEMSTONE-304: a phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
  

  Abstract Presenter: Jin Li
• 08:20 – 08:28 CEST

  SO-10: Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
  

  Abstract Presenter: Taroh Satoh
• 08:28 – 08:38 CEST

  Discussant: O-3, O-4, SO-10
  

  Discussant: Florian Lordick, MD, PhD – Leipzig University Medical Center
• 08:38 – 08:48 CEST

  O-5: Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG
  

  Abstract Presenter: Anna D. Wagner, MD – Lausanne University Hospital, University of Lausanne
• 08:48 – 08:56 CEST

  SO-9: The relationship between primary tumour infiltrating immune cells and immune activation status of tumour draining lymph nodes in oesophageal cancer patients – results from the UK MRC OE02 trial
  

  Abstract Presenter: Maximilian Kloft
• 08:56 – 09:04 CEST

  SO-11: Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT)
  

  Abstract Presenter: Zev A. Wainberg, MD, Msc – UCLA School of Medicine
• 09:04 – 09:12 CEST

  SO-12: CLDN18.2 expression in resectable gastroesophageal cancers: associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intratumor heterogeneity
  

  Abstract Presenter: Antonella Cammarota
• 09:12 – 09:25 CEST

  Discussant: O-5, SO-9, SO-11, SO-12
  

  Discussant: Kohei Shitara, MD – National Cancer Center Hospital East